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Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally 
advanced or metastatic disease. In this setting the goal of treatment is to prolong survival and to 
control disease- and treatment-related symptoms. Currently systemic cytotoxic chemotherapy 
remains the first-line treatment for most patients with stage IV NSCLC, but preferred treatments are 
now defined by histology and based on the presence of specific molecular abnormalities. In first-
line the combination of platinum plus pemetrexed with or without bevacizumab is a reasonable 
choice in patients with non-squamous NSCLC. Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs) as first-line therapy are the recommended for patients with EGFR-
sensitizing mutations. A small-molecule TKI of anaplastic lymphoma kinase (ALK), crizotinib, 
showed pronounced clinical activity in the treatment of patients with NSCLC positive for EML4-
ALK and it has rapidly entered into daily clinical practice. Currently no agents are specifically 
approved for the treatment of squamous cell carcinoma of the lung. Second-line treatments include 
docetaxel, pemetrexed, or erlotinib as single agents. There is a growing evidence that cytotoxics are 
better than EGFR-TKIs in EGFR wild-type patients. In the setting of the third line, the only 
approved agent is erlotinib. In elderly patients with good performance status (PS), doublet 
chemotherapy including platinum should not be excluded, especially for those patients 70–75 years 
of age without comorbidities. The better selection of patients, the identification of specific 
predictive biomarkers, a reasonable sequencing of all active and available treatments, including 
targeted therapies and cytotoxic, may significantly contribute to extend the natural history of stage 
IV NSCLC. 
Lung cancer remains a relevant health care problem and in the near future will account for almost 
30% of all cancer-related deaths. Non-small cell lung cancer (NSCLC) represents more than 80% of 
all lung cancer cases. The majority of patients with lung cancer are diagnosed at baseline with 
locally advanced or metastatic disease. The increase in life expectancy with the associated 
cumulative increase in the risk of cancer has led to an increased incidence of this disease in the 
elderly population. Overall the incidence and death rates for lung cancer are decreasing for both 
men and women
1
; however, the 5-year survival in stage IV NSCLC remains as low as 1%.
2
 
According to the current World Health Organization (WHO) classification for lung tumors, NSCLC 
includes many histological subtypes, but for therapeutic purposes it can be broadly categorized as 
squamous and non-squamous. This non-canonical categorization is related to the lack of efficacy of 
some cytotoxic agents (eg, pemetrexed) or to an excess of toxicity for some targeted agents (eg, 
bevacizumab and other multiple vascular endothelial growth factor [EGFR] inhibitors) in squamous 
histology. As consequence over the last few years the histological definition became progressively 
more important in tuning the therapeutic choices and now is definitively recognized the role of 
immunohistochemistry in minimizing the amount of NSCLC not otherwise specified (NOS). 
Here, we summarize the available data about the best treatment strategy in front line for stage IV 
NSCLC on the basis of the predictive role of histology and new molecular findings and reviews 
new data about the treatment customization in elderly patients, as well as treatment choices in 
second line and beyond. 
Treatment Choices In First Line 
The Role of Cytotoxic Chemotherapy 
First-line chemotherapy improves survival in patients with advanced NSCLC and good 
performance status (PS). It generally includes two chemotherapy agents with different mechanisms 
of action and safety profiles.
3 and 4
 Several studies
5, 6, 7 and 8
 and multiple meta-analyses
9, 10 and 11
 
established the superior efficacy of doublet regimens over single agents and the superior activity of 
cisplatin over carboplatin in terms of objective response rate (ORR)
12
 despite a less favorable 
toxicity profile. Improvements in survival were observed in subgroups of cisplatin-treated patients 
who had been treated with third-generation platinum-based regimens (hazard ratio [HR] for 
mortality with carboplatin relative to cisplatin = 1.11; 95% confidence interval [CI], 1.01–1.21) and 
in patients with non-squamous histology (HR = 1.12; 95% CI, 1.01–1.23). 
A decade ago several large randomized clinical trials compared different platinum-based doublets 
(including third-generation agents such taxanes, gemcitabine, or vinorelbine) without showing 
significant differences in ORR, progression-free survival (PFS), and overall survival (OS).
13, 14 and 15
 
A meta-analysis investigated the role of adding a third agent to platinum-based doublets and 
showed that triplets are associated with an increase in ORR, which does not translate into a better 
PFS or OS rate.
16
 Traditionally, the histologic subtype did not matter for the choice of 
chemotherapy but the therapeutic landscape changed following the results of a large phase III 
randomized non-inferiority study conducted in 1,725 patients with stage IIIB or IV NSCLC that 
compared cisplatin plus pemetrexed (CP) to cisplatin plus gemcitabine (CG). A preplanned analysis 
for histology showed that patients with non-squamous histology benefited more from CP in terms 
of OS (HR 0.81; P = .005), while PFS did not differ between the two groups. On the contrary, 
patients with squamous cell histology showed a marginally significant superiority in OS when 
treated with CG (10.8 v 9.4 months, respectively; HR 1.23; P = .05) and PFS was also significantly 
longer (5.5 v 4.4 months, respectively; HR 1.36; P<.05). CP resulted in a statistically significant 
inferior incidence of grade 3–4 neutropenia, anemia, thrombocytopenia, febrile neutropenia, and 
alopecia (P ≤.001), whereas drug-related grade 3–4 nausea was higher (P = .004). 17 and 18 
Hypothesis-generating findings support the superior activity of pemetrexed in non-squamous 
NSCLC on the basis of the differential expression of thymidylate synthase (TS), one of the target 
enzymes of pemetrexed, among the different histotypes of lung cancer being TS lower in 
adenocarcinoma than in squamous cell carcinoma.
19
 Supportive data indicate extremely high levels 
of TS in small cell lung cancer where pemetrexed did not show activity.
20
 
Nab-paclitaxel is a biologically interactive albumin-bound paclitaxel and in a phase II trial showed 
improvement of clinical outcomes with weekly rather than every-3-week administration.
21
 
Subsequently, a phase III randomized trial evaluated nab-paclitaxel plus carboplatin (nab-PC) 
versus standard-paclitaxel plus carboplatin (sb-PC). Nab-PC demonstrated a significantly higher 
ORR than sb-PC (33% v 25%; P = .005). Although ORR by histology was not a prespecified 
endpoint of the study, nab-PC was significantly more active than sb-PC in patients with squamous 
histology. nab-PC was as effective as sb-PC in patients with non-squamous histology. In general, 
nab-PC was better tolerated, with lower rates of grade 3 and 4 neuropathy, neutropenia, arthralgia, 
and myalgia. 
22
 
Molecular Agents Inhibiting Tumor Angiogenesis 
Angiogenesis involves multiple cellular events and many interactions among a variety of cell types. 
While the primary stimulus for angiogenesis in the tumor microenvironment is the hypoxia-driven 
activation of hypoxia-inducible factor-1α (HIF-1α), and the subsequent activation of vascular 
endothelial growth factor (VEGF), numerous other growth factors and protein products of 
oncogenes and tumor-suppressor genes are also involved.
23
 Tumor-associated vasculature fails to 
mature completely, typically due to the development of hypoxic regions in the tumor that stimulate 
a perpetual cycle of VEGF production, angiogenesis, and further tumor growth.
24
 
Vascular Endothelial Growth Factor and Receptor Inhibitors 
Bevacizumab, an anti-VEGF humanized monoclonal antibody which inhibits the interaction 
between the ligand and VEGF receptors (VEGFRs), has been the first targeted agent approved for 
the treatment of first-line of metastatic non-squamous NSCLC. The activity of bevacizumab in 
combination with chemotherapy has been evaluated in two large phase III clinical trials (Eastern 
Cooperative Oncology Group [ECOG] trial E4599 and AVAstin in Lung Cancer [AVAiL]). ECOG 
4599 randomly assigned 855 PS 0–1 patients with advanced non-squamous NSCLC to receive 
carboplatin-paclitaxel with or without bevacizumab. The primary endpoint of the study was OS. 
Patients with squamous histology, those with a history of hemoptysis, brain metastases, bleeding or 
thrombotic disorders, or the need for anticoagulation were also excluded from the study. The 
exclusion of patients with squamous histology was mandated from life-threatening or fatal episodes 
of hemoptysis observed in a phase randomized II trial of bevacizumab plus chemotherapy.
25
 All the 
efficacy endpoints were significantly improved with bevacizumab (median OS 12.3 months v 10.3 
months [HR 0.80; P = .003] and median PFS 6.2 v 4.5 months, respectively [HR 0.66; P<.001]). 
26
 
Subgroup analyses suggested that the magnitude of benefit was greater in patients with 
adenocarcinoma (OS was 14.2 v 10.3 months; HR 0.69). 
27
 To date, no biomarkers, including 
hypertension, have been identified to reliably predict patients with improved survival from the 
addition of bevacizumab.
28
 
Bevacizumab was also evaluated in combination with cisplatin plus gemcitabine in the another 
(AVAiL) study in 1,050 patients testing two different dose levels, 7.5 and 15 mg/kg, and having as 
the primary endpoint PFS. The addition of bevacizumab significantly increased PFS from 6.1 to 6.5 
or 6.7 months (in the high- and low-dose groups, respectively; HRs for PFS were 0.75; P = .0003 
and .85; P = .04). No difference in OS was observed. ORR was also significantly higher in both 
bevacizumab arms (37.8%, P<.0001, and 30.6%, P = .0002, respectively) versus 21.6% for the 
chemotherapy arm. 
29
 Treatment with bevacizumab was generally well tolerated, even if more 
severe bleeding episodes were observed in the bevacizumab arm (4.4% v 0.7%, respectively; 
P<.001). 
The reasons why these two studies ended up in partially different results is not known, but it could 
be partially related to differences in the patient cohorts, the inferior activity of paclitaxel and 
carboplatin versus cisplatin and gemcitabine, and the in vitro evidence of synergy between taxanes 
and bevacizumab.
30
 
Despite the modest OS benefit and the conflicting data bevacizumab added chemotherapy was 
recommended and progressively implemented in several therapeutic guidelines in patients with 
stage IV non-squamous NSCLC with good PS and without brain metastases and haemoptysis.
31, 32, 
33, 34 and 35
 
Recently a systematic review and meta-analysis of four randomised phase II/III trials confirmed that 
bevacizumab significantly prolonged OS (HR 0.90; P = .03), and PFS (0.72; P<.001). 
Bevacizumab also showed a significantly greater effect on OS in patients with adenocarcinoma 
versus other histologies (P = .02), and in patients with body weight loss ≤5% versus>5% (P = .03). 
36
 
Patients with CNS metastases were initially excluded because of the risk of cerebral hemorrhage. 
Nevertheless, the available data suggest an equal risk of intracranial bleeding in patients with CNS 
metastases treated with or without bevacizumab. In a phase II study (PASSPORT) the safety of 
bevacizumab in patients with advanced NSCLC and PS 0–1 previously treated for brain metastases 
(including whole-brain radiation therapy, radiosurgery, and/or neurosurgery) was prospectively 
evaluated. Patients received bevacizumab in combination with platinum-based doublet 
chemotherapy or erlotinib as front-line treatment, while second-line bevacizumab was added to the 
investigators' treatment choice (erlotinib, pemetrexed, docetaxel). Bevacizumab was administered at 
the dose of 15 mg/kg every 21 days until disease progression or unacceptable toxicity for a 
maximum of 1 year. The primary objective of the study was the incidence of symptomatic grade ≥2 
CNS hemorrhage. One hundred fifteen patients were enrolled and full-dose anticoagulation was 
allowed. Brain imaging was performed at screening and then every 6–8 weeks. No episode (grade 
15) of CNS hemorrhage was reported. Other toxicities were consistent with those previously 
reported.
37
 Additional safety data came from ARIES (Avastin Registry: Investigation of 
Effectiveness and Safety), a prospective observational cohort study in colorectal cancer and NSCLC 
that included patients underrepresented in randomized clinical trials, ie, elderly patients, with poor 
PS, or with CNS metastasis. Among 150 patients with NSCLC and CNS metastases no episodes of 
CNS bleeding were documented.
38
 A retrospective exploratory analysis of 13 randomized trials 
evaluated the safety of bevacizumab in patients with pre-existing brain metastases or with brain 
metastases detected when patients were already receiving bevacizumab.
39
 Three of these studies 
included patients with NSCLC for a total of 8,443 patients of whom 4,760 received bevacizumab. 
Occult brain metastases were identified in 187 of 8,443 patients (91 in bevacizumab arms and 96 in 
non-bevacizumab arms). Three patients (3.3%) in the bevacizumab group developed a grade 4 
cerebral hemorrhage, compared with one of 96 control patients (1%) who experienced a grade 5 
cerebral hemorrhage. Mortality rate was not different between the two groups.
25, 26 and 29
 
SaiL (Safety of Avastin in Lung) is another large phase IV study undertaken to assess the safety and 
efficacy of first-line bevacizumab combined with several standard chemotherapy regimens in 
patients with advanced or recurrent non-squamous NSCLC
40
 and another open-label trial 
(ATHENA)
41
 evaluated the safety of bevacizumab in patients with CNS metastases and breast 
cancer. One hundred eighty-one of the 2,166 patients in SAiL (8.4%) and 140 of the 2,216 patients 
in ATHENA (6.3%) developed brain metastases. Six of these patients were treated with 
bevacizumab after diagnosis of CNS metastases, none of whom developed cerebral hemorrhage. 
Three patients in the SAiL study (0.9% of the patients in the two studies who developed brain 
metastases) had cerebral hemorrhage, only one grade 3. In the ATLAS study (The Avastin Tarceva 
Lung Adenocarcinoma Study)
42
 patients with advanced NSCLC who had already treated with an 
induction treatment including bevacizumab, in the absence of disease progression, were randomly 
assigned in the maintenance portion of the study either to continue bevacizumab alone or in 
combination with erlotinib. Patients with treated brain metastases were allowed; only one patient 
developed a grade 2 cerebral hemorrhage after disease progression. A further review of 57 trials that 
included 10,598 patients evaluated the safety and efficacy of different anti-VEGF therapies 
(bevacizumab in 22 trials, sorafenib in 12, sunitinib in 5, and a variety of other agents in 18). Brain 
metastases were an exclusion criterion in 76% of the trials.
43
 In the studies that excluded patients 
with brain metastases (1,755 patients) only two episodes of CNS bleeding were reported (<1%). In 
the four studies that included patients with brain metastases (2688 patients) there were no episodes 
of intracranial hemorrhage. In conclusion, several retrospective studies and at least one prospective 
study confirmed that bevacizumab may be safely used in patients with brain metastases. 
In AVAiL, patients remained on study if anticoagulation for venous thrombosis was started while 
the patient was already treated. Nine percent of patients received therapeutic anticoagulation with 
either warfarin or low-molecular-weight heparin, and no pulmonary hemorrhages were observed. A 
retrospective analysis was performed to assess the effect of anticoagulation in AVAiL and in other 
two randomized trials in metastatic colon cancer.
44
 There were no severe (grade 3) pulmonary 
hemorrhages in any of the patients receiving anticoagulation and treated with bevacizumab. In 
SAiL, 15% of patients received concomitant anticoagulation at some point during treatment, and the 
overall risk of grade ≥3 bleeding was low (4%), as well as the risk of grade ≥3 pulmonary 
hemorrhage (1%). Among 1065 patients who completed one or more cycles of bevacizumab, a total 
of 227 bleeding events occurred in 181 patients (17%) versus 19 bleeding events in 15 of 87 
patients (17.2%) receiving anticoagulants.
45
 Therefore, anticoagulation does not increase the risk of 
bleeding during treatment with bevacizumab. 
Data about the safety of bevacizumab in patients with a poor PS are limited. A preliminary report 
from ARIES included 182 patients with a PS of ≥2. These patients had a worse clinical outcome in 
terms of PFS and OS compared to the general population. 
Several retrospective analyses were performed to identify the potential risk factors associated with 
pulmonary hemorrhage (PH) in patients treated with bevacizumab,
46
 including central tumor 
location, cavitation, and vessel invasion especially in patients on anticoagulant therapy. None of the 
clinical or radiological features proved to be reliable predictive factors for severe PH. Major blood 
vessel and bronchial vessel infiltration, encasement, and abutting may predict PH. However, 
standardized radiological criteria for defining vessel infiltration have not been established. 
Hypothetically, dilation of the bronchial artery could be a risk factor for PH, but no conclusive data 
exist to support this hypothesis. A high-resolution computed tomography scan should be used to 
assess PH occurring in non-squamous NSCLC patients treated with bevacizumab.
47
 
Recently, two small studies investigating bevacizumab in combination with chemo-radiotherapy 
reported an alarmingly high rate of tracheal-esophageal fistula formation.
48
 However, another study 
has reported acceptable toxicity
49
 and additional studies are ongoing. 
Because of the higher efficacy of pemetrexed and bevacizumab in non-squamous NSCLC these two 
agents have been recently tested with carboplatin in a series of clinical studies. In a multicenter 
phase II study bevacizumab and pemetrexed maintenance after an initial therapy with pemetrexed 
and carboplatin plus bevacizumab was assessed.
50
 The study showed an ORR of 55% with a 
favorable toxicity profile. Median PFS and OS were 7.8 and 14.1 months, respectively. These 
promising results led to the subsequent phase III (PointBreak) randomized study of 
pemetrexed/carboplatin plus bevacizumab as induction followed by pemetrexed and bevacizumab 
maintenance compared with paclitaxel/carboplatin plus bevacizumab as induction followed by 
bevacizumab maintenance in chemotherapy-naive patients with advanced non-squamous NSCLC.
51
 
The primary endpoint of superior OS for the pemetrexed arm was not met (12.6 v 13.4 months, HR 
1.00, P = .949); however, the study showed a modest improvement in PFS for the pemetrexed arm 
(6.0 v 5.6 months, HR 0.83, P = .012) and a good safety profile. 
52
 
A post hoc analysis of patients ≥70 years of age in ECOG 4599 previously detected increased 
adverse events and numerically decreased survival benefit associated with bevacizumab compared 
to patients <70 years of age. A pooled analysis of ECOG 4599 and PointBreak data based on age 
was recently presented.
53
 The statistically significant benefit associated with the addition of 
bevacizumab to chemotherapy was consistently reported across all age groups<75 years. Patients 
≥75 years receiving bevacizumab had a higher incidence of grade ≥3 adverse events relative to 
chemotherapy alone with no statistically significant survival benefit, although increased grade ≥3 
adverse events were observed in all age groups. 
Another phase III study (PRONOUNCE) evaluated pemetrexed/carboplatin followed by 
maintenance therapy with pemetrexed compared with bevacizumab plus paclitaxel/carboplatin 
followed by maintenance therapy with bevacizumab. The primary endpoint was PFS without grade 
4 toxicity (G4PFS) according to a superiority study design.
54
 Top line data indicate that 
pemetrexed/carboplatin was not superior to carboplatin/paclitaxel/bevacizumab in terms of G4PFS 
and no difference in PFS or OS between the two regimens were observed. 
Ramucirumab is an investigational monoclonal antibody that binds to VEGFR-2 and blocks ligand 
binding and activation.
55
 A phase II open-label study is currently evaluating ramucirumab as first-
line therapy in combination with carboplatin/paclitaxel, with preliminary results from the first 15 
patients reporting an overall RR of 67%.
56
 Another phase II trial is recruiting patients with 
previously untreated NSCLC to examine ramucirumab in combination with four different 
chemotherapeutic regimens as first-line therapy, and a phase III trial is recruiting patients with 
NSCLC to test ramucirumab in combination with docetaxel as second-line therapy after failure of 
platinum-based therapy. 
Multi-targeted Anti-angiogenetic Agents 
Efforts to identify drugs that inhibit key pathways involved in the pathogenesis of cancer have led 
to the development of multi-targeted agents. Small-molecule TKIs that inhibit receptors such as 
VEGFR, platelet-derived growth factor receptor (PDGFR), Raf, and KIT simultaneously may offer 
advantages over agents with single targets, and therefore a higher likelihood of single-agent 
activity. In addition, as multi-targeted TKIs are often available orally they may be more convenient 
for patients. Conversely, a potential disadvantage is the potential for toxicity resulting from off-
target kinase inhibition, and additive toxicity, which may be particularly relevant when the agents 
are combined with chemotherapy. 
Sorafenib is a Raf and VEGFR inhibitor (VEGFR-2 and VEGFR-3) with activity against PDGFR 
and KIT. In xenograft models, sorafenib plus vinorelbine, cisplatin or gefitinib resulted in tumor 
growth delay at least comparable to that observed with each agent alone. The phase III ESCAPE 
trial tested carboplatin plus paclitaxel with or without sorafenib as first-line treatment in advanced 
NSCLC. The primary endpoint of OS was not met and the study was terminated early due to the 
detrimental effect of sorafenib in patients with squamous cell carcinoma and the lack of effect in 
non-squamous cell carcinoma.
57
 Similarly, another phase III study (NExUS) evaluated sorafenib 
with gemcitabine plus cisplatin did not meet the primary endpoint of OS. Patients with squamous 
histology were excluded from this study based on the results of ESCAPE.
58
 
Motesanib, a VEGFR-1, -2, and -3, PDGFR, KIT, and RET inhibitor was investigated in multiple 
tumor types including NSCLC. In a phase II trial (n = 186) motesanib was combined with 
carboplatin and paclitaxel and showed comparable efficacy to bevacizumab plus carboplatin and 
paclitaxel.
59
 In a phase III trial (MONET1), 1,090 patients with advanced non-squamous NSCLC 
received carboplatin and paclitaxel with or without motesanib; preliminary results reported that 
neither PFS (5.6 v 5.4 months; HR 0.785; P = .006) nor OS (13.0 v. 11.0 months; HR 0.897; P = 
.137) were significantly improved and grade ≥3 adverse events were more frequent with motesanib. 
60
 
Vascular-Disrupting Agents 
Vascular-disrupting agents (VDA) are compounds that directly target blood vessels and create 
central tumor necrosis. VDAs have demonstrated signs of clinical activity in different tumor 
types,
61
 including NSCLC.
62 and 63
 A phase III study in front-line investigated paclitaxel/carboplatin 
with or without ASA404 was terminated early because an interim analyses showed no increase in 
OS.
64
 
As a class of agents, the clinical development is hampered by cardiovascular and neurological 
toxicities as single agents, and by hematologic toxicity in combination with chemotherapy and 
currently there is no predictive marker to identify patients with a high probability of response. 
Epidermal Growth Factor Receptor Pathway 
Tyrosine Kinase Inhibitors 
EGFR is a transmembrane protein with cytoplasmic kinase activity that transduces growth factor 
signaling from the extracellular milieu to the cell. More than 60% of NSCLCs express EGFR and 
this receptor is now a relevant therapeutic target for the treatment of these tumors. TKIs of EGFR 
are especially effective in patients whose tumors harbor activating mutations in the EGFR gene and 
several trials have concluded that initial therapy with a EGFR-TKI instead of chemotherapy is the 
best treatment choice in patients with tumors harboring a sensitizing mutation (Table 1). Therefore, 
mutation testing is mandatory to identify these patients, given that selection based only on clinical-
pathologic characteristics is inadequate. They include never-smoking status, female gender, the 
histologic diagnosis of adenocarcinoma, and the Asiatic ethnicity. 
Table 1.  
Phase III Randomized Studies Comparing TKIs to Platinum-Based Chemotherapy as First-
Line Treatment in “Selected” NSCLC 
Study Treatment 
EGFR Mutational 
Status 
 ORR 
(%) 
PFS (mo) OS (mo) 
Test 
Performed 
(%) 
Test 
Positive 
(%) 
IPASS
74
 
Gefitinib v 
Carbo/Placli 
35.9% 59.7% 
43.0 v 
32.3 
5.7 v 5.8 18.6 v 17.3 
    
  P = 
.0001 
  HR: 0.74   HR: 0.91 
     
  95% CI: 
0.65–0.85 
  95% CI: 
0.76-1.10 
     
  P<.0001   P = .11 
First-
SIGNAL
76
 
Gefitinib v Cis/Gem 31.6% 43.7% 
53.5 v 
45.3 
6.1 v 6.6 21.3 v 23.3 
    
  P = .153   HR: 0.81   HR: 1.00 
     
  95% CI: 
0.64–1.03 
  95% CI: 
0.75-1.34 
     
  P = .044   P = .428 
WJTOG
78
 Gefitinib v Cis/Doce 100% 100% 
62.1 v 
32.2 
9.2 v 6.3 30.9 v nr 
    
  P<.0001   HR: 0.49   HR: 1.64 
     
  95% CI: 
0.34–0.71 
  95% CI: 
0.75-3.58 
     
  P<00001   P = .211 
NEJ002
79
 
Gefitinib v 
Carbo/Placli 
100% 100% 
73.7 v 
30.7 
10.8 v 5.4 30.5 v 23.6 
    
  P<.001   HR: 0.30   P = .31 
     
  95% CI: 
0.22–0.41  
     
  P<.001 
 
OPTIMAL
80
 
Erlotinib v 
Carbo/Gem 
100% 100% 
83.0 v 
36.0 
13.1 v 4.6 ns 
    
  P<.0001   HR: 0.16 
 
     
  95% CI: 
0.10–0.26  
     
  P<.0001 
 
EURTAC
81
 Erlotinib v platinum 100% 100% 
63.6 v 
17.8 
9.7 v 5.2 19.3 v 19.5 
 
 based chemotherapy
⁎
 
  
  P<.0001   HR: 0.37   HR: 1.04 
     
  95% CI: 
0.25–0.54 
  95% CI: 
065-1.68 
     
  P<.0001   P = .87 
Study Treatment 
EGFR Mutational 
Status 
 ORR 
(%) 
PFS (mo) OS (mo) 
Test 
Performed 
(%) 
Test 
Positive 
(%) 
LUX-Lung 
3
88
 
Afatinib v Cisplatin/ 100% 100% 
56.0 v 
23.0 
11.1 v 6.9 NR 
 
 Pemetrexed 
  
  P<.0001   HR: 0.58 
 
     
  95% CI: 
0.43–0.78  
     
  P = 
.0004  
LUX-Lung 
6
89
 
Afatinib v 
Cisplatin/Gemcitabine 
100% 100% 66.9 v 23 
11.0 v 5.6 
 HR:0.28 
OS based 
on 43% of 
events 
shows 
    
  P<.0001   P<.0001    HR=.95 
      
   P=.7593 
Abbreviations: Cis, cisplatin; Gem, gemcitabine; Carbo, carboplatin; Pacli, paclitaxel; Doce, 
docetaxel; ns, not specified; nr, not reached 
ORR, objective response rate; PFS, median progression-free survival; OS, median overall 
survival; HR, hazard ratio; CI, confidence interval; NR, not reported. 
Platinum-based chemotherapy options: Cis/Gem or Cis/Doce or Carbo/Doce or Carbo/Gem. 
Gefitinib and erlotinib are first-generation TKIs that selectively target EGFR. Looking back to early 
single -agent studies with gefitinib (IDEAL-1 and IDEAL-2), initially performed in unselected and 
previously treated patients, some anti-tumor activity was shown with response rates ranging from 
12%–18%, a disease control rate of 42%–54%, with most of the responses achieved within 4–5 
weeks, and when patients responded a considerable tumour shrinkage was observed. Activity was 
superior in adenocarcinoma, females, and never-smokers.
65 and 66
 
These results and the preclinical evidence in preclinical models of a synergism with chemotherapy 
led to two large randomized phase III trials that explored the efficacy of gefitinib in combination 
with platinum-based chemotherapy. Both studies did not demonstrate any statistically significant 
difference in OS between arms and similar results were reported with erlotinib.
67, 68, 69, 70, 71 and 72
 A 
confirmation of the limited efficacy of EGFR-TKIs in unselected patient population came from the 
Iressa Survival Evaluation in Lung Cancer (ISEL) trial, a large multicenter phase III trial that 
compared single-agent gefitinib versus placebo in 1,692 patients with advanced NSCLC after 
failure of one or two prior chemotherapies and OS was comparable in the two arms.
73
 
The Iressa Pan-Asia Study (IPASS) trial was performed in a clinically selected population of Asian 
adenocarcinoma patients, who were never-smokers or with limited smoking history (≤10 pack-years 
and ≥15 years since quitting) and involved nine countries across Asia. One thousand two hundred 
seventeen patients were randomized to first-line gefitinib or carboplatin-paclitaxel and the primary 
end point of the study was the non-inferiority of gefitinib.
74
 The results showed the superiority of 
PFS for gefitinib compared with chemotherapy in the entire study population (HR 0.74). EGFR 
mutation analysis was performed on 437 patients (35.9%) and, of these, 60% were positive for one 
of the panel of 29 mutations detected by the EGFR kit (DxS, Rotor-Gene Q 5plex, QIAGEN, GER). 
Among the 261 known EGFR mutants, the benefit of first-line gefitinib was even stronger with a 
further improvement in PFS (HR 0.48), an increased RR (71% on gefitinib v 47% on 
chemotherapy). Final OS data based on 78% of the events, showed no differences between gefitinib 
and chemotherapy in the entire population (18.6 v 17.3 months, respectively; HR 0.91, P = .11) and 
in the mutation-positive subgroup (HR 1.00). In addition, patients with EGFR-mutated tumors in 
the gefitinib group had a clinically relevant improvement in quality of life and a lower incidence of 
grade 3–4 adverse events compared to chemotherapy. 
A second study randomized 313 Korean never-smokers with adenocarcinoma to gefitinib or 
cisplatin–gemcitabine. Overall, there was no significant difference between the arms in terms of 
PFS or OS. Similarly to IPASS, gefitinib improved PFS versus chemotherapy in mutation-positive 
patients (without reaching the statistical significance) but worsened PFS in mutation-negative 
patients. OS did not differ between the groups regardless of EGFR status.
76
 
The results of the IPASS trial were really practice-changing because of both the impressive results 
in the EGFR mutation-positive group and the fact that the EGFR mutation-negative patients treated 
with gefitinib did fairly poor (PFS HR 2.85). These results showed that it is harmful to treat patients 
who do not harbor EGFR mutations with first-line EGFR-TKIs, even if they are never-smokers with 
adenocarcinoma, and that patients are best screened by genotype testing to determine the most 
appropriate first-line treatment. 
The efficacy of EGFR-TKIs in EGFR mutation-positive patients has been further confirmed in three 
prospective randomised studies performed in Asiatic patients, 
77 and 78
 as well as in one study in 
Caucasian patients.
79
 In all of these studies EGFR-TKIs were associated with a more favorable 
toxicity profile and improved quality of life. OS ranged from 21.6–30.5 months and was highly 
influenced by high cross-over rates, with up to 95% of patients receiving EGFR-TKIs after failure 
of chemotherapy, suggesting that these agents are effective independently from the line of therapy. 
The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines in 2009 
recommended gefitinib as first-line treatment for patients with activating EGFR mutations. If EGFR 
mutation is negative or unknown, the recommendation favors cytotoxic chemotherapy. 
32
 
A retrospective study investigated the initial impact of erlotinib or gefitinib versus chemotherapy on 
the risk of CNS progression in patients with EGFR mutations. One hundred fifty-five patients were 
considered (EGFR-TKI n = 101, chemotherapy n = 54). The HR of CNS progression for EGFR-
TKIs versus chemotherapy was 0.56 (95% CI, 0.34–0.94). If prospectively validated these data 
indicate that the treatment with EGFR-TKIs prevent CNS metastases in NSCLC with EGFR 
mutations. 
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In all studies with EGFR-TKI, it was observed that inevitably, despite the significant improvement 
in PFS and OS, all patients develop resistance. Mutations in the tyrosine kinase domain that render 
tumors resistant to erlotinib and gefitinib are the most common mechanism of resistance. The 
threonine-790–methionine (T790M) point mutation was identified in about half of the patients 
whose disease progressed during EGFR-TKI therapy and is rarely detected in untreated patients. 
Other mechanisms of resistance include c-MET overexpression (15%–20% of cases), in-frame 
duplications and/or insertion in exon 20 (5% of the cases), and unknown mechanisms, which 
account for about 25%–30%.81 and 82 
Irreversible inhibitors of EGFR are a class of agents with the potential to overcome EGFR-TKI 
resistance. Afatinib (BIBW2992) is an irreversible ErbB-family blocker with potent activity against 
NSCLC harboring activating EGFR mutations and/or the gatekeeper mutation T790M, albeit at 
lower potency. It has been recently evaluated in several clinical trials with promising results. 
83, 
84 and 85
 The LUX-Lung 3 was a phase III trial of afatinib versus CP as first-line treatment for 
patients with advanced adenocarcinoma harboring EGFR-activating mutations. Patients treated with 
afatinib had a median PFS, the primary endpoint of the study, of 11.1 versus 6.9 months for 
chemotherapy (HR 0.58; P = .0004). ORR was also significantly higher with afatinib (56% v 23%, 
P<.001), reporting a consistent delay in time to deterioration of cancer-related symptoms. 
Recently the results of LUX-Lung 6 have been presented. This study compared the safety and 
efficacy of first-line afatinib versus gemcitabine plus cisplatin (GC) in Asiatic patients with EGFR 
mutation-positive tumors. Following central testing for EGFR mutations, 364 patients were 
randomized 2:1 to daily afatinib 40 mg or GC (1,000 mg/m
2
 day 1, 8 + 75 mg/m
2
 every 21 days 
intravenously up to six cycles). PFS, the primary endpoint of the study, was significantly prolonged 
with afatinib compared with GC (median PFS 11.0 v 5.6 months, HR .28, P<.0001). Objective 
response (66.9% v 23.0%, P<.0001) and disease control (92.6% v 76.2%, P<.0001) rates were 
significantly higher with afatinib. Patient reported-outcomes (PROs) showed significantly better 
control of cancer-related dyspnea, cough, and pain with afatinib. Adverse events in both arms were 
as expected, with a more favorable safety profile with afatinib ( Table 1).
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A phase II trial of afatinib versus gefitinib as first-line treatment (LUX-lung 7) in advanced NSCLC 
is currently recruiting patients with EGFR activating mutations. 
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Another oral pan-HER inhibitor, dacomitinb (PF-00299804) with affinity for EGFR, HER2, and 
HER4, also has shown activity in NSCLC. A multinational, multicenter, randomized, open-label, 
phase 3 study comparing the efficacy and safety of dacomitinib to gefitinib is currently enrolling 
patients with locally advanced or metastatic NSCLC with EGFR-activating mutations having as 
primary of the study PFS (NCT01774721).
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The different generations TKI and new agents in development, including EGFR-TKI agents against 
T790 mutation are summarized in Table 2. 
Table 2.  
Different Generations of EGFR Kinase Inhibitors 
First Generation Second Generation Third Generation (mutant-selective) 
Gefitinib XL647 WZ4002 
Erlotinib Afatinib CO-1686 
Lapatinib Icotinib AP26113 
Canertinib Neratinib TAS-2913 
 
Dacomitinib AZD9291 
  
Z650 
Monoclonal Antibodies Anti-EGFR 
Cetuximab is a chimeric monoclonal antibody that selectively binds the extracellular domain of the 
EGFR on the tumor cells and inhibits the receptor-associated tyrosine kinase activation.
89 and 90
 A 
handful of randomized trials have evaluated the addition of cetuximab to chemotherapy, with two 
completed phase III trials.
91, 92, 93 and 94
 The First-Line Erbitux in Lung Cancer (FLEX)
77
 trial 
enrolled 1,125 patients with EGFR-expressing tumors randomized to receive cisplatin 80 mg/m
2
 
day 1 and vinorelbine 25 mg/m
2
 days 1 and 8 (each cycle repeated every 3 weeks for up to six 
cycles) or the same chemotherapy plus cetuximab. OS was modestly improved with cetuximab 
(11.2 v 10.1 months; HR 0.871; P<.044). The response rate was also improved (36% v 29%; 
P<.01). PFS was 4.8 months in both arms. The marginal OS benefit was observed in all histologic 
subgroups and there was no difference in quality of life between the study arms, although 
compliance with serial quality-of-life questionnaires was low. The main cetuximab-related toxicity 
was acne-like rash, which occurred in 10% of patients enrolled in the trial. Comparable results were 
observed in another trial, evaluating the addition of cetuximab to carboplatin plus paclitaxel or 
docetaxel. Three separate meta-analyses evaluated data from these two phase III trials and from 
other two randomized phase II trials comparing chemotherapy ± cetuximab 
95, 96 and 97
 (Table 3). 
Among the 2,018 considered patients (1,003 in the cetuximab arm and 1,015 in the control arm), 
those treated with cetuximab had a 9% reduction in the risk of disease progression (HR 0.91; 
P<.06), a 13% reduction in the risk of death (HR 0.87; P<.004), and an approximately 50% increase 
in ORR (P<.0001). 
75
 The combination of cetuximab plus chemotherapy induced more grade 3/4 
rash (5.2% v 1%, P<.000), diarrhea (2.3% v 1.1%, P<.003), neutropenia (19.5% v 16.1%, P<.029), 
and infusion reactions (3.9% v 0.9%, P<.000). 
Table 3.  
Clinical Trials of Cetuximab and Chemotherapy Combination Versus Chemotherapy Alone 
Study Phase 
Trial 
Size (n) 
Treatment 
Median PFS 
(mo) 
Median OS 
(mo) 
Butts et al 
(2007)
94
 
II 65 
Cis or Carbo/Gem/Cet 
v Cis or Carbo/Gem 
5.09 v 4.21 12.0 v 9.3 
Rosell et al 
(2008)
95
 
II 86 
Cis/Vino/Cet v 
Cis/Vino 
5.0 v 4.6 8.3 v 7.3 
Pirker et al 
(2009) 
FLEX
96
 
III 
1125 
Cis/Vino/Cet v 
Cis/Vino 
4.8 v 4.8 HR = 
0.943 (0.825–
1.77) P = .39 ns 
11.3 v 10.1 HR 
= 0.87 (0.76–
0.996) P = .044 
557 Cet 
arm 
568 
Control 
arm 
Lynch et al 
(2010) 
BMS099
97
 
III 
676 
Carbo/pacli or 
Doce/Cet v Carbo/pacli 
or Doce/Cet 
4.40 v 4.24 HR 
= 0.9 (0.76–
1.07) P = .236 
ns 
9.69 v 8.38 HR 
= 0.89 (0.75–
1.05) P = .169 
ns 
338 Cet 
arm 
338 
Control 
arm 
Abbreviations: Cis, cisplatin; Gem, gemcitabine; Carbo, carboplatin; Pacli, paclitaxel; Doce, 
docetaxel; Vino, vinorelbine; Cet, cetuximab; HR,hazard ratio; ns, not significant; OS, 
overall survival; PFS, progression-free survival. 
In vitro data indicate that high levels of EGFR expression correlate with sensitivity to 
cetuximab,
98 and 99
 but a retrospective analysis of the FLEX study suggested that EGFR protein 
expression by immunohistochemistry is an inadequate predictor of the efficacy of EGFR-targeted 
therapy. Immunohistochemistry (IHC) measurement of EGFR intensity and frequency on tumor 
cells was used to generate, on a continuous scale of 0–300, an EGFR IHC score for each assessable 
patient study in order to investigate whether tumor EGFR expression levels were associated with a 
predictive role. Treatment outcomes were analysed in patients with low (<200) and high (≥200) 
EGFR IHC scores, representing 69% and 31% of evaluable patients, respectively.
100
 For patients 
with a high EGFR IHC score, median OS was longer in the chemotherapy plus cetuximab arm than 
in the control arm (12.0 v 9.6 months, respectively; HR 0.73, P = .011), without significant increase 
in cetuximab-related side effects. No corresponding survival benefit was observed in the group of 
patients with low EGFR IHC score (median OS of 9.8 v 10.3 months, respectively; HR 0.99, P = 
.88). EGFR expression level was not predictive at all of cetuximab benefit in first-line treatment of 
recurrent/metastatic squamous cell carcinoma of the head and neck (EXTREME) and K-ras wild-
type metastatic colorectal cancer (CRYSTAL). 
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Based on existing inconsistent evidence cetuximab is currently not licensed for the treatment of 
advanced NSCLC even if cetuximab is recommended in combination with chemotherapy based on 
a lower level of evidence by the National Comprehensive Cancer Network practice guidelines for 
advanced/metastatic NSCLC.
102
 
Nevertheless, EGFR remains a important target for molecularly based therapies and currently 
another fully humanized monoclonal antibody targeting the EGFR extracellular domain III, 
necitumumab, is under investigation in two large phase III studies having the potential benefit of 
lower hypersensitivity reaction risk compared with cetuximab and also equivalent antibody-
dependent cell-mediated cytotoxicity.
103
 Recently the phase III study evaluating the addition on 
necitumumab to pemetrexed and cisplatin in non-squamous NSCLC was prematurely closed due to 
concerns about the risk of thromboembolic events in the experimental arm.
104
 Accrual in the phase 
III trial of necitumumab in combination with gemcitabine and cisplatin in squamous NSCLC is 
completed.
105
 
Anaplastic Lymphoma Kinase Inhibitors 
In NSCLC the role of targeted therapies has been further reinforced with the identification of the 
EML4-ALK (anaplastic lymphoma kinase) fusion gene, a genetic abnormality detected in the 4%–
6% of the adenocarcinomas of the lung,
106
 and the concomitant identification of a targeted agent, 
crizotinib, which is highly active in ALK-translocated tumors. ALK gene rearrangement is 
associated with specific clinical-pathological features, including male sex, young age, absent or 
minimal smoking history, adenocarcinoma histology, and usually mutual exclusivity between 
EML4-ALK and EGFR and KRAS mutations.
107, 108 and 109
 
Crizotinib is a MET inhibitor that also has activity on ALK and c-ROS1 oncogene (ROS1) 
pathways. It was first studied in humans in a phase I/II study (PROFILE 1001), with a standard 
dose-escalation pharmacokinetic schema followed in a second stage by clinical efficacy assessment. 
Preliminary results from the phase I study clearly demonstrated clinically relevant tumor shrinkage 
in the majority of enrolled patients.
110
 On this basis, an expansion cohort of 82 NSCLC patients 
harboring the ALK rearrangement were enrolled to receive the recommended dose of crizotinib 250 
mg twice daily. The ORR was 57% (46 partial responses and one complete response). An additional 
33% of patients had stable disease at the 8-week assessment.
111
 An update of this study confirmed a 
ORR of 61% and the median PFS was 10 months.
112
 Based on the encouraging response rate of the 
phase I study, a large multicenter second-line study and beyond in ALK-positive NSCLC patients 
was performed. Patients characteristics largely corresponded to those of the previous study and the 
ORR was of 51%.
113
 In both the phase I and phase II trials, the majority of responses was achieved 
during the first 8 weeks of treatment and duration of response was 48.1 and 41.9 weeks, 
respectively. Patients included in the phase I trial had a survival probabilities at 6 and 12 months of 
90% and 81%, respectively. Crizotinib gained approval by the US Food and Drug Administration 
(FDA) in August 2011 for any line of treatment in locally advanced or metastatic NSCLC, ALK-
positive based on the outcome in terms of response rate of the abovementioned studies. 
The high level of activity of crizotinib in ALK-positive NSCLC patients has been recently 
confirmed in a phase III study evaluating crizotinib versus pemetrexed or docetaxel as second-line 
treatment. The study met its primary endpoint demonstrating the superiority of crizotinib over the 
standard chemotherapy in prolonging PFS (7.7 v 3.0 months, respectively; HR 0.49, P<.0001). 
ORR was significantly higher in patients treated with crizotinib (65% v 20%, P<.0001) and the 
safety profile was acceptable. An interim analysis of OS showed no significant improvement with 
crizotinib as compared with chemotherapy (HR 1.02; P = .54). Better control of disease-related 
symptoms and improvement in quality of life have been reported with crizotinib. 
114
 
As already described, thymidylate synthase (TS) level may predict the sensitivity to pemetrexed-
based chemotherapy in different histological subtypes of NSCLC, being inversely correlated with 
pemetrexed efficacy. A recent study evaluating the role of pemetrexed-based chemotherapy in 
ALK-positive NSCLC patients, showed lower TS levels than the median values in unselected 
NSCLC. A low TS level has been observed in almost 83% of the evaluated cases (P = .039) and the 
few ALK-positive NSCLC patients with high TS levels had poorest survival outcome. 
115
 These 
findings suggest that differences in TS expression levels in ALK-positive NSCLC patients may 
predict the differential responses to pemetrexed but also justify the major efficacy of pemetrexed 
compared to docetaxel in this subset of patients, as observed in the PROFILE 1007 trial. 
The phase III trial PROFILE 1014 (NCT01154140) is currently the only study actively recruiting 
patients for the evaluation of crizotinib versus cisplatin or carboplatin plus pemetrexed as first-line 
treatment for previously untreated ALK-positive non-squamous NSCLC patients. The primary 
endpoint of the study is PFS, while ORR and OS are secondary endpoints. A superiority phase III 
trial with the same schedule of treatment has been designed for the East-Asian population, but the 
study is not yet open for accrual.
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Although there are clinical–pathological features associated with ALK rearrangement they do not 
properly select patients for ALK inhibitors and, consequently, molecular testing is mandatory. 
There are three methods of detecting ALK rearrangement: the fluorescence in situ hybridization 
(FISH) break-apart assay, IHC, and reverse-transcriptase polymerase chain reaction (RT-PCR). 
Currently FISH is the gold standard and is the approved companion diagnostic test (Vysis ALK 
break apart FISH probe kit; Abbott Molecular, USA) by the US FDA.
117, 118 and 119
 
Several second-generation ALK inhibitors are under development and some are more potent and 
selective than crizotinib in terms of higher response rates or activity in patients who have acquired 
resistance to crizotinib. LDK378 is being developed as an alternative to crizotinib, based on 
increased potency and specificity. 
In a phase I study, LDK378 was investigated in 123 ALK-positive patients with NSCLC
120
 and the 
ORR in the 114 evaluable patients treated at 400 mg/d or more was 58%. Activity was essentially 
the same in crizotinib-resistant and crizotinib-naïve patients, 57% and 60%, respectively. The 
median PFS and median duration of response (DOR) were 8.6 and 8.2 months, respectively. 
Treatment with LDK378 was reasonably tolerated.
121
 Two phase III trials are planned in ALK-
positive NSCLC: in the first study LDK378 will be compared with single-agent chemotherapy after 
progression on a platinum based doublet and on crizotinib,
122
 while the second study in first-line 
treatment will compare LDK378 with a platinum-based doublet.
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CH5424802 is another potent selective orally available ALK inhibitor. In a multicenter, phase I/II 
study, 46 patients with ALK-positive NSCLC were treated with CH5424802 in the phase II portion 
of the study at the dose level of 300 mg twice daily; none had received prior treatment with an ALK 
inhibitor. An objective response was observed in 93% of the patients, including two complete and 
41 partial responses.
124
 
AP26113 is a TKI that potently inhibits mutant activated forms of ALK-positive and EGFR-
mutated tumors, and TKI-resistant forms including L1196M (ALK) and T790M (EGFR). AP26113 
does not inhibit native EGFR. Currently a phase I/II open-label multicenter study is ongoing in 
patients with advanced malignancies (except leukemia) refractory to available therapies or for 
whom no standard treatment exists. AP26113 has promising anti-tumor activity in ALK-positive 
patients, with initial evidence of activity in EGFR-mutated patients, and is generally well tolerated. 
Phase II will be initiated after the recommended phase II dose will be defined in four different 
cohorts: crizotinib-naïve NSCLC; crizotinib-resistant NSCLC; EGFR TKI-resistant NSCLC; and 
other tumors
125
 (Table 4). 
Table 4.  
Second-Generation ALK Inhibitors 
ALK Inhibitors Phase n ORR (n) ORR (%) PFS 
LDK378 I 88 62 79 8.6 mo (95% CI. 4.3–19.3) 
CH5424802 I/II 46 43 93.5 — 
AP26113 I/II 18 10 56 — 
Abbreviations: ORR, objective response rate; PFS, median progression-free survival. 
Early Palliative Care 
The symptom burden of patients with lung cancer is extensive and includes loss of appetite, 
dyspnea, and other symptoms that lead to decreased quality of life. A landmark study examined the 
benefit of early palliative care integrated with standard oncologic care versus standard oncologic 
care and palliative care only “as needed” on patient-reported outcomes, the use of health services, 
and the quality of end-of-life care among patients with metastatic NSCLC. The study was a 
prospective, nonblinded, randomized, controlled trial of outpatients conducted at a single center. 
Quality-of-life scores improved significantly in patients assigned to intervention compared with 
standard care. A 2.7-month difference in median survival (P = .02) in favor of the group assigned to 
early palliative care was also observed, although survival was not a primary end point of the trial. 
This outcome needs to be validated in future studies. 
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Second-Line Treatment 
Single Agents 
Although cytotoxic chemotherapy and/or molecularly targeted agents as first-line treatments may 
delay disease progression and prolong survival, almost all of patients develop progressive disease 
and require additional therapies. The choice of treatment at relapse or progression depends on PS, 
comorbidity, histology, molecular characteristics, and, obviously, patient preference. Second-line 
therapy should be considered in patients with a good PS with clinical or radiological progression 
because this approach is associated with symptom palliation and increased survival in selected 
patients.
127 and 128
 The benefit of second-line treatment also affects the outcome with first-line 
therapy. In a systematic review it was shown that post-progression survival is highly associated 
with OS for first-line chemotherapy, whereas PFS is only moderately associated with OS.
129
 
Single-agent docetaxel or pemetrexed and erlotinib are currently registered options. Other cytotoxic 
agents that are active as initial therapy also may have activity, but they have not been compared in 
randomized trials in previously treated patients with either best supportive care (BSC) or approved 
agents.
130
 
Supportive evidence for the approval of docetaxel as second-line therapy came from a couple of 
small phase III studies.
131 and 132
 Although the every-3-week schedule of docetaxel is considered a 
standard of care recent data indicate the weekly schedule (33.3 mg/m
2
 to 40 mg/m
2
 for 6 weeks 
followed by a 2-week rest) as an equally effective treatment but less toxic as clearly concluded by a 
meta-analysis.
133
 In a pivotal phase III study pemetrexed demonstrated to be non-inferior to 
docetaxel in terms of efficacy with a toxicity profile favoring pemetrexed.
134
 Retrospective data 
showed a differential activity of pemetrexed by histology with better survival with pemetrexed in 
patients with non-squamous histology (9.3 months v 8 months; P ≤.048), whereas patients with 
squamous cell histology did better with docetaxel (7.4 months v 6.2 months; P<.018). 
135 and 136
 
Few studies have evaluated the combination of two cytotoxic agents in second-line and all these 
trials have failed to demonstrate superiority of the two-drug combination over docetaxel.
137, 138, 139, 
140, 141 and 142
 
In the second-/third-line setting erlotinib in a phase III study in chemotherapy-refractory patients, 
without limitation for EGFR status and histology, was demonstrated to be modestly superior to 
placebo. The ORR to erlotinib was 8.9%, with an additional 36% of patients achieving stable 
disease. There was a significant improvement in PFS (2.2 v 1.8 months; HR 0.61; P = .001) and 
median survival time (6.7 v 4.7 months; HR 0.70; P = .001) favoring erlotinib. The effect of 
erlotinib on survival was similar across most of the considered subsets. Never-smokers and patients 
with EGFR-positive tumors had the larger survival benefit. 
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In a similar study, gefitinib versus placebo failed to demonstrate improved survival in truly 
chemotherapy-refractory patients (ISEL trial).
71
 However, the subset of Asian origin showed 
significant improvement in survival. 
In a phase IIb/III trial in stage IIIB/IV patients with adenocarcinoma who had received one or two 
previous chemotherapy regimens and with disease progression after at least 12 weeks of treatment 
with reversible EGFR-TKIs, afatinib was tested against placebo. Although there was no benefit in 
terms of OS (10.8 v 12.0 months; HR 1.08) median PFS was longer in the afatinib arm (3.3 v 1.1 
months; HR 0.38; 95% CI, 0.31–0.48), as well as more patients reached an objective response (29 v 
1 patient). 
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Only one small randomized phase II study compared gefitinib with erlotinib in the this setting in 96 
patients who failed to respond to first-line chemotherapy and had either EGFR mutation or at least 
two out of three clinical factors associated with a higher incidence of EGFR mutations. 
Both gefitinib and erlotinib showed activity and tolerable toxicity profiles.
144
 
Several randomized studies that compared an EGFR-TKI versus chemotherapy in unselected or 
EGFR wild-type patients are summarized in Table 5 and Table 6. All of these studies indicate a 
marginal or detrimental effect of EGFR TKIs on PFS, especially in EGFR wild-type patients, 
without registering any difference in terms of OS.
75, 76, 77, 78, 79, 80, 81, 82 and 83
 This information is fully 
consistent with the concept of the superior efficacy of EGFR-TKIs in EGFR-mutant tumors even in 
the context of additional lines of therapy. 
Table 5.  
Randomized Trials Comparing EGFR-TKI Versus Chemotherapy in Advanced NSCLC in 
EGFR Unselected Patients 
Trial Regimen n 
Median PFS 
(mo) 
HR (95% 
CI) 
Median OS 
(mo) 
HR (95% 
CI) 
INTEREST 
Gefitinib 733 2.2 1.04 (0.93–
1.18) 
7.6 
1.02 (0.91–
1.15) 
Docetaxel 733 2.7 8.0 
 
V15-32 
Gefitinib 245 2.0 0.90 (0.72–
1.12) 
11.5 
1.12 (0.89–
1.40) 
Docetaxel 244 2.0 14.0 
 
Trial Regimen n 
Median PFS 
(mo) 
HR (95% 
CI) 
Median OS 
(mo) 
HR (95% 
CI) 
ISTANA 
Gefitinib 82 3.3 0.73 (0.53–
1.00) 
14.1 
0.87 (0.61–
1.24) 
Docetaxel 79 2.4 12.2 
 
HORG 
Erlotinib 166 3.6 
NR 
7.9 NR 
Pemetrexed 166 2.7 8.9 
 
TITAN 
Erlotinib 203 1.4 1.19 (0.97–
1.46) 
5.3 
0.96 (0.78–
1.19) 
Docetaxel/pemetrexed 221 2.0 5.5 
 
DELTA 
Erlotinib 151 2.0 1.22 (0.97–
1.55) 
14.8 
0.91 (0.68–
1.22) 
Docetaxel 150 3.2 12.2 
 
Abbreviations: PFS, progression-free survival; HR, hazard ratio; OS, overall survival; CI, 
confidence interval; NR, not reached. 
Table 6.  
Randomized Trials Comparing EGFR-TKI Versus Chemotherapy in Advanced NSCLC in 
EGFR Wild-Type Patients 
Trial Regimen n 
Median PFS 
(mo) 
HR (95% 
CI) 
Median OS 
(mo) 
HR (95% 
CI) 
INTEREST Gefitinib 106 1.7 1.24 (0.94–
1.64) 
6.4 1.02 (0.78–
1.33) 
 
Docetaxel 123 2.6 6.0 
TITAN Erlotinib 75 1.4 1.25 (0.88–
1.78) 
6.4 
0.85 (0.59–
1.22) 
 
Docetaxel/Pemetrexed 74 2.0 4.5 
 
TAILOR Erlotinib 107 2.4 
1.45 (1.08–
1.92)  
N.A. 
 
Docetaxel 104 3.4 
   
DELTA Erlotinib 109 1.3 1.45 (1.09–
1.94) 
9.0 0.98 (0.69–
1.39) 
 
Docetaxel 90 2.9 10.1 
Abbreviations: PFS, progression-free survival; HR, hazard ratio; OS, overall survival; CI, 
confidence interval; NA, not available. 
Heat shock protein 90 (Hsp90) is a molecular chaperone required for the stability of a number of 
conditionally activated and/or expressed signalling proteins, as well as multiple mutated, chimeric, 
and overexpressed signalling proteins, that promote cancer cell growth and/or survival. Ganetespib 
is a novel, second-generation Hsp90 inhibitor with a favorable safety profile, active as single agent 
especially in ALK-positive NSCLC.
145
 Based on synergistic preclinical interactions between 
docetaxel and ganetespib, a phase II study enrolled 255 adenocarcinoma patients previously treated 
with one line of therapy. Co-primary endpoints were PFS in patients with elevated lactate 
dehydrogenase (LDH) or in tumors harboring KRAS mutations. The study demonstrated that 
ganetespib in combination with docetaxel had an acceptable safety profile with an improvement in 
OS and PFS compared to docetaxel alone. The improvements in OS and PFS were substantially 
enhanced in patients with a diagnosis of advanced disease>6 months and the observed improvement 
in survival does not appear to be associated with EGFR or KRAS mutational status.
146
 A phase III 
study in second line in patients with advanced adenocarcinoma progressing>6 months from 
diagnosis is currently ongoing. 
A recent meta-analysis
147
 of randomized trials evaluated the efficacy and safety of single agent 
erlotinib versus different combinations of molecular targeted agents in second line. Eight eligible 
trials were identified, involving 2,417 patients. The intention-to-treatment (ITT) analysis 
demonstrated that combinations of targeted therapies significantly improved OS (HR 0.90, P = 
.024), PFS (HR 0.83, P = .018), and ORR (OR 1.35, P = .04). In the subgroup analyses based on 
type of studies, EGFR status and KRAS status there was a tendency to improve PFS and OS in 
combining targeted therapies, except that for patients with EGFR mutation or wild-type KRAS, 
which favored single-agent erlotinib. Additionally, grade 3 or 4 rash, fatigue, and hypertension were 
more frequently reported with combinations of targeted therapy. Based on the results of each 
individual studies included in the abovementioned meta-analysis, there is no convincing evidence 
supporting the use of combinations of targeted agents in second line, mainly because of the lack of 
OS benefit and for the higher toxicity profile of the combinations that reduce the trade-off between 
activity and toxicity,. The same conclusions may be applied to the combination of cytotoxic agents 
with a wide array of targeted therapies. 
Lung cancer is a progressive and dynamic genetic process that leads to acquisition of several 
alternative escape mechanisms that overcome the simple drug interference on one or two pathways 
(eg, EGFR/VEGFR or EGFR/MET). For this reason it is mandatory to continuously search for 
specific predictive biomarkers with the goal to identify subtypes of NSCLC responsive to the 
different biological agents. The inclusion of unselected populations of NSCLC patients in clinical 
trials should be abandoned. 
Treatment Opportunities Beyond Second Line 
Treatment options for patients whose tumors have failed to respond to two or more conventional 
chemotherapy regimens are limited, with erlotinib and crizotinib being the only agents currently 
approved as third-line therapy for patients with advanced/metastatic NSCLC. 
The efficacy of gefitinib and erlotinib as third-line therapy was assessed retrospectively through the 
Taiwan Cancer Registry and the National Insurance claim databases. Among 984 patients recruited, 
the two agents showed comparable OS (median, 10.2 v 9.9 months; P = .524) and TTF (median, 5.5 
v 3.4 months; P = .103). At multivariate analyses, both treatments had similar risk of overall 
mortality (adjusted HR 1.04, P = .629) and treatment failure (adjusted HR 0.94, P = .417). 
Subgroup analyses based on age, tumor histology, and gender also did not reveal differences in OS 
and TTF. For patients who received gefitinib or erlotinib for more than 3 or 6 months, there was no 
difference in TTF, but patients who received erlotinib had longer OS. 
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The paucity of approved agents for third-line therapy and beyond constitutes an important unmet 
medical need.
149
 Several targeted agents, including some with multiple targets, have been or are 
currently being evaluated as third- and fourth-line therapy. 
In a large study (ZEST) vandetanib, an orally administered inhibitor of VEGFR, EGFR, and RET, 
was compared with erlotinib after failure of one or two prior chemotherapy regimens. The study 
failed to show improvement in either PFS or OS.
150
 Similarly in the ZEPHYR trial, which 
compared vandetanib with placebo after failure of one to two prior chemotherapy regimens, 
including a prior EGFR-TKI, vandetanib did not increase OS, although it significantly improved 
PFS (HR 0.6; P<.0001), ORR (2.6% v 0.7%; P = .028), and disease control rate at 8 weeks (30% v 
16%; P<.0001). 
151
 
Single-agent sorafenib, a raf kinase and angiogenesis inhibitor, was investigated in a phase II study 
in heavily pretreated patients (two or more lines of therapy) using a randomized discontinuation 
design. Patients received 400 mg of sorafenib orally twice daily for two cycles (step 1). Responding 
patients continued on sorafenib, while progressing patients went off study. Patients with stable 
disease were randomized to receive placebo or sorafenib with a cross-over from placebo allowed 
upon progression. Two hundred ninety-nine patients were evaluable for step 1 and 81 eligible 
patients were randomized on step 2. The 2-month disease control rates after randomization were 
54% and 23% for sorafenib and placebo, respectively (P = .005). The HR for progression of step 2 
significantly favored sorafenib and there was also a trend for an improved survival. 
152
 These data 
were the background for the subsequent double-blind, placebo-controlled, multicenter phase III 
study (MISSION), which assessed whether third-/fourth-line treatment with sorafenib plus best 
supportive care would improve OS relative to best supportive care plus placebo in patients with 
relapsed/refractory NSCLC of predominantly non-squamous histology. A total of 703 patients were 
randomized with baseline demographic data and prior treatments generally well balanced. Median 
OS was similar in the two groups, whereas PFS, TTF, ORR, and disease control rate were 
significantly greater in the sorafenib group. Rates of all and serious adverse events were higher in 
the experimental arm.
153
 Based on these data, no further development of sorafenib in this setting has 
been planned. 
Apatinib (YN968D1) is a multiple kinase inhibitor with in vitro activity against VEGFR-2, 
PDGFR-beta, c-Kit, and c-src.
154
 In addition, it counteracts the effects of multidrug resistance 
conferred by ABCB1 and ABCG2 proteins at concentrations lower than those associated with 
kinase inhibition.
155
 Results of a phase II randomized, placebo-controlled, study in patients with 
non-squamous NSCLC after two previous treatment regimens was conducted in China. Among 135 
patients randomized to receive apatinib at the dose of 750 mg or placebo orally once daily until 
disease progression or unacceptable toxicity, median PFS was 4.7 months for apatinib and 1.9 
months for placebo (HR 0.28). Response rate and disease control rate were also significantly better 
in the experimental arm. Adverse events known to be associated with anti-angiogenetic multiple 
TKI agents were generally mild or moderate in severity and manageable.
156
 
Incorporation of genetic analysis for a better selection of treatments beyond second line is quite 
likely a future requirement at least in the context of clinical trials, but it yields additional and more 
complicated challenges and perspectives. This task may be particularly challenging in the second- 
and third-line settings, where the availability of tissue for molecular analysis is often limited and not 
routinely collected.
157
 
Even if at the present time repeat biopsies outside of a specific trial setting are not a requirement 
given the relative infrequency of clearly actionable targets with readily available treatments, it is 
equally important to recognize we have made huge progress in our understanding of molecular 
oncology that led to some of the new treatment options based on a greater emphasis on tissue 
collection and identifying relevant mutations. 
The Emerging Role Of Immunotherapy 
Despite the limited efficacy of immunotherapy in the treatment of lung cancer in the past and the 
various mechanisms that lung cancer can use to thwart the immune system attack, vaccines are 
currently being evaluated in phase III trials, and checkpoint inhibitors show potential promise in 
NSCLC.
158
 
A phase I trial of nivolumab, an anti–PD-1 antibody (BMS-936558) administered once every 2 
weeks, included a large dose expansion cohort of patients with NSCLC. Patients with advanced 
NSCLC who had been previously treated with a prior platinum-containing regimen were eligible 
but could have received no more than five prior treatment regimens for their advanced disease. 
Besides being included in the dose-escalation portion of the trial, patients with NSCLC were 
randomly assigned to 1, 3, and 10 mg/kg to include equal numbers of squamous and non-squamous 
cell histology at each dose level. A total of 122 patients with NSCLC were enrolled, of whom 76 
were assessable for response at the time of data analysis. The majority of patients with NSCLC 
were heavily pretreated; 55% of patients received at least three prior lines of therapy. Fourteen 
patients had objective responses (18%). Responses were seen at all dose levels studied and in 
squamous as well as non-squamous histology. Interestingly, tumor PD-L1 expression may be 
associated with tumor response. Patients without tumor expression of PD-L1 had no documented 
tumor responses, but 36% of patients with tumor PD-L1 expression were objective responders.
159
 
Long follow-up data of this cohort of patients showed an encouraging sustained OS across 
histologies with a median survival time exceeding 9 months
160
 (Table 7). MPDL328A, a human 
monoclonal antibody containing an engineered Fc domain designed to optimize efficacy and safety 
that targets PD-L1, blocking PD-L1 from binding its receptors, including PD-1 and B7.1 has been 
tested recently in a phase I expansion study in NSCLC. Early efficacy data indicate an ORR of 24% 
observed in squamous and non-squamous histology, including several responses with rapid tumor 
shrinkage.
161
 Preliminary data from a phase II study of nivolumab in combination with 
chemotherapy have been recently presented.
162
 
Table 7.  
Phase I Trials of Anti–PD-1 and Anti–PD-L1 Antibodies in NSCLC 
Agents Phase Treatment N ORRs 
OS, mo 
(95% CI) 
Anti–
PD-1
160
 
I 
Nivolumab in 
previously treated 
advanced NSCLC 
122 
16% Non- 
squamous 15% 
Squamous 19% 
9.6 (7.4-
13.7) 9.6 
(5.3-13.7) 
9.2 (7.6- 
NR) 
Anti–
PD-1
162
 
I 
BMS-936558 plus 
platinum-doublets in 
chemotherapy-naive 
NSCLC 
43 A arm: 12 
(squamous) B arm: 
15 (non-squamous) C 
arm: 16 (3 squamous 
+ 13 non-squamous) 
33%, 33%, 31% — 
Anti–
PD-
L1
161
 
I MPDL3280A 37 
24% PD-L1 tumor 
status–positive 
100% (4/4) PD-L1 
tumor status–
negative 15% 
(4/26) 
— 
Abbreviations: PT-doublet, platinum-based doublet chemotherapy with (A) 
nivolumab/gemcitabine/cisplatin or (B) nivolumab/pemetrexed/cisplatin; or (C) 
nivolumab/carboplatin/paclitaxel; ORR, objective response rate; OS, overall survival; CI, 
confidence interval. 
Systemic Treatment In The Elderly 
Based on the outcome of phase III studies
163 and 164
 single-agent vinorelbine or gemcitabine has been 
the recommended treatment for most patients with stage IV NSCLC who are aged 70–79 years.31 
Older fit patients are often considered unable to tolerate platinum-based systemic therapy. 
A retrospective analysis of ECOG 5592, a phase III trial in which chemotherapy-naive patients with 
stage IIIB or IV NSCLC were randomized to cisplatin plus either etoposide or paclitaxel, showed in 
elderly patients more treatment-related toxicity but comparable ORR and OS with the overall 
treated patients.
165
 The combined assessment of six studies of the combination of docetaxel plus 
gemcitabine revealed no difference in efficacy according to age, but showed an increase in the 
incidence of mucositis in elderly patients.
166
 However, in a phase III trial (Multicenter Italian Lung 
Cancer in the Elderly Study) conducted in patients ≥70 years old the combination of 
vinorelbine/gemcitabine did not show an advantage over single agent gemcitabine or vinorelbine in 
terms of quality of life and OS.
168
 
In a Japanese trial (JCOG 0207) 126 patients ≥70 years with stage III/IV advanced NSCLC and a 
PS of 0–1 were randomized to docetaxel (20 mg/m2) and cisplatin (25 mg/m2) weekly for 3 weeks 
every a 28-day cycle compared with docetaxel (25 mg/m
2
) alone with the same schedule. The trial 
stopped early at the second interim analysis because of a survival benefit favoring the combination 
in the subgroup of patients who were 70–74 years of age (HR 0.23; P ≤.077). The rate of grade 3/4 
neutropenia, anemia, and anorexia were higher in the combination arm. In those patients ≥75 years 
of age, toxicity was higher without any OS benefit. 
167
 Another Japanese study compared the same 
weekly schedule of cisplatin and docetaxel with docetaxel alone administered every 3 weeks in 
chemotherapy-naive patients ≥70 years and PS 0–1. This study failed to demonstrate any advantage 
of the combination over single agent.
168
 
The French multicenter randomized phase III trial (IFCT 0501) successfully compared a platinum-
based combination versus single-agent therapy.
169
 Carboplatin (area under the concentration curve 
[AUC] 6 on day 1) and paclitaxel (90 mg/m
2
 on days 1, 8, and 15 every 28 days) was compared 
with either vinorelbine (25 mg/m
2
 on day 8 every 21 days) or gemcitabine (1,150 mg/m
2
 on days 1 
and 8 every 21 days). ORR (27% v 10%, P<.0001), median PFS (6.0 v 2.8 months, P<.0001), and 
median survival time (10.3 v 6.2 months; HR 0.64; P<.001) were significantly longer in the 
combination compared with the single -agent arm. Toxicity was increased in the combination arm 
with higher rate of grade 3/4 neutropenia, febrile neutropenia, thrombocytopenia, anemia, and 
sensory neuropathy, as well as treatment-related deaths (4.1%). 
A subset analysis of a trial already mentioned demonstrated that in patients age ≥70 years nab-
paclitaxel plus carboplatin versus standard paclitaxel and carboplatin showed a significant increase 
in OS (19.9 v 10.4 months; P = .009). 
170
 
In 2010, the Elderly Task Force of the European Organization of Research and Treatment of Cancer 
and Lung Cancer Group and the International Society for Geriatric Oncology published a 
systematic review on the treatment of NSCLC in elderly patients. It was recommended to consider 
two-drug combinations in selected elderly patients with a good PS and a lack of significant 
comorbidities.
171
 
Systemic Treatment In Poor Performance Status Patients 
As in other cancers PS has a defined prognostic role in advanced NSCLC and in PS 2 patients 
median survival is 3–5 months with 1-year survival<20%.172 PS 2 patients usually account for a 
small proportion of patients enrolled in trials and for this reason the strength of existing 
recommendations for this type of patients is quite weak.
173
 The ECOG 1594 trial randomly assigned 
patients to one of four different platinum based double-agent chemotherapy regimens. It was 
observed an excessive rate of adverse events among PS 2 patients, which led to a hold on 
enrollment of these patients in the early phase of the study. This observation contributed to the 
exclusion of PS 2 patients from subsequent trials investigating platinum-based therapy.
174
 The 
Cancer and Leukemia Group B (CALGB) 9730 trial was a phase III trial that compared carboplatin 
and paclitaxel to paclitaxel. PS 2 patients assigned to doublet experienced a significantly higher 
ORR, better median survival time, and a statistically significant higher 1-year OS rate.
7
 Furthermore 
a retrospective review confirmed that the combination of carboplatin and paclitaxel in PS 2 patients 
had a toxicity rate similar to that observed in PS 0–1 patients.175 A combined analysis compared 
single-agent (gemcitabine or vinorelbine) versus carboplatin and paclitaxel and confirmed a higher 
ORR and median TTP with the combination without significant difference in OS.
176
 A prospective 
phase III trial of carboplatin and gemcitabine compared with gemcitabine alone revealed a 
significantly higher ORR (21.1% and 6.1%, P<.01), which did not translate in any statistically 
significant improvement in median PFS (3.8 and 2.7 months, P = .14) or OS (6.7 and 5.1 months, P 
= .24). 
177
 
More recently another phase III trial assessed carboplatin and pemetrexed with pemetrexed alone. 
Patients treated with doublet chemotherapy experienced a significantly higher ORR (24% v 10.5%, 
P = .029), longer PFS (HR 0.46; P<.001; median PFS 5.9 v 3.0 months, respectively), and OS (HR 
0.57; P<.001; median OS 9.1 v 5.6 months, respectively). 
178
 
Limited amount of data are available for targeted agents. Erlotinib was compared with carboplatin 
and paclitaxel in first-line for patients with PS 2. This study showed a lower PFS and OS compared 
with chemotherapy.
179
 A randomized trial comparing gefitinib versus placebo in patients not 
candidates for chemotherapy with PS 2–3 revealed no advantage in OS and PFS for patients 
receiving gefitinib. Only in the subgroup with FISH-positive EGFR was there a statistically 
significant advantage in PFS.
180
 
To date, no standard of care exists for patients with advanced NSCLC and PS 2; in these patients, 
clinical assessment and risk-benefit ratio must be taken into account in the choice of treatment. 
Conclusions 
Most of the newly diagnosed patients with NSCLC have metastatic disease and for these patients 
there are many new emerging treatment options currently in clinical trials aiming to further improve 
survival beyond the boundaries reached with cytotoxic chemotherapy. To date, histology as a 
surrogate marker and in the context of the different lines of therapy, has already influenced efficacy 
outcomes. Improvements have been made in extending survival in selected groups of patients with 
tumors harbouring specific genomic alterations without a significant impact on the overall 
population of patients with advanced NSCLC. Only the discovery through systematic search of 
homogeneous subgroups of tumours with the same genetic characteristics and the search for 
individualized approaches could represent the way to improve survival expectancy for these 
patients. Some progress has been made targeting two of the major biological pathways in lung 
cancer, the EGFR and VEGFR pathways, and deepening our knowledge about the mechanisms of 
tumor growth and differentiation mediated by these markers or associated molecules. EGFR-TKIs 
should be the preferred front line treatment choice for advanced patients with non-squamous tumors 
with EGFR-sensitizing mutations. For the minority of patients harboring ALK gene rearrangements, 
the preferred treatment is represented by crizotinib. Second generation and more potent ALK 
inhibitors are currently in development and have already demonstrated activity in crizotinib-
resistant patients. For all other non-squamous NSCLC patients, the doublet of a platinum agent with 
pemetrexed or the triplet combination of carboplatin plus paclitaxel and bevacizumab are 
recommended treatment options. Standard of care for patients with advanced squamous cell 
carcinoma remains doublet chemotherapy. Second-line therapies include single-agent docetaxel, 
pemetrexed, and erlotinib. Re-challenge with the same combination doublet used in first line 
remains an experimental option that needs validation and may be eventually considered in 
extremely fit patients with a long-lasting tumor response or disease stabilization. Treatment options 
for patients whose tumors have failed to respond to two or more conventional chemotherapy 
regimens are limited; erlotinib and crizotinib are the only agents currently approved in many 
countries as third-line therapy for patients with advanced/metastatic NSCLC. Targeted agents in 
development may contribute to the unmet need in third line and beyond, and agents with multiple 
targets may have the potential for greater efficacy with acceptable toxicity profiles. Biomarker 
correlates will likely be the key to identifying those patients most likely to benefit from newer 
targeted agents. 
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